JPH1017580A - Production of crystalline l-ascorbic 2-phosphorate sodium salt - Google Patents
Production of crystalline l-ascorbic 2-phosphorate sodium saltInfo
- Publication number
- JPH1017580A JPH1017580A JP8169962A JP16996296A JPH1017580A JP H1017580 A JPH1017580 A JP H1017580A JP 8169962 A JP8169962 A JP 8169962A JP 16996296 A JP16996296 A JP 16996296A JP H1017580 A JPH1017580 A JP H1017580A
- Authority
- JP
- Japan
- Prior art keywords
- aps
- crystalline
- ascorbic
- amorphous
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 159000000000 sodium salts Chemical class 0.000 title claims description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 22
- 239000003960 organic solvent Substances 0.000 claims abstract description 17
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 7
- 239000010452 phosphate Substances 0.000 claims abstract description 7
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims abstract description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- -1 aliphatic alcohols Chemical class 0.000 claims description 10
- 239000002612 dispersion medium Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000002211 L-ascorbic acid Substances 0.000 claims description 6
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 abstract description 10
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 150000000996 L-ascorbic acids Chemical class 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 3
- 239000002270 dispersing agent Substances 0.000 abstract 3
- 229910052708 sodium Inorganic materials 0.000 abstract 3
- 239000011734 sodium Substances 0.000 abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000001914 filtration Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- HYHGLHONPBPZGJ-YCWPWOODSA-L disodium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] phosphate Chemical compound [Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP(O)([O-])=O)=C1[O-] HYHGLHONPBPZGJ-YCWPWOODSA-L 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、L−アスコルビン
酸−2−リン酸エステルナトリウム塩の結晶(以下、L
−アスコルビン酸−2−リン酸エステルナトリウム塩を
APSと略記し、L−アスコルビン酸−2−リン酸エス
テルナトリウム塩の結晶を結晶質APSと略記する)の
製造方法に関する。結晶質APSは、L−アスコルビン
酸の安定化誘導体として有用であり、化粧料、医薬品、
食品添加物用、飼料用、その他各種の工業分野に使用さ
れる。TECHNICAL FIELD The present invention relates to a crystal of L-ascorbic acid-2-phosphate sodium salt (hereinafter referred to as L-ascorbic acid-2-phosphate).
-Ascorbic acid-2-phosphate sodium salt is abbreviated as APS, and crystals of L-ascorbic acid-2-phosphate sodium salt are abbreviated as crystalline APS). Crystalline APS is useful as a stabilized derivative of L-ascorbic acid, for cosmetics, pharmaceuticals,
It is used for food additives, feed, and various other industrial fields.
【0002】[0002]
【従来の技術】L−アスコルビン酸(ビタミンC)は多
様な生理作用、薬理作用を持つことが知られていたが、
なかでもメラニン色素沈着防止への効果があることから
美白化粧料に用いられてきた。L−アスコルビン酸は、
酸素、熱に対して不安定であり、この不安定なL−アス
コルビン酸の2位の水酸基をリン酸エステル化すること
により、酸素、熱に対して安定化することが出来るのは
公知の事実であり、L−アスコルビン酸−2−リン酸エ
ステルの塩、特にナトリウム塩、すなわちAPSの形
で、水に溶け易いビタミンC誘導体として使われてい
る。現在市販されているAPSは非晶質であるため、保
存時に吸湿しやすく粉末の団塊を生じ易い。吸湿したA
PSはケーキングを生じたり、流動性が低下するため、
他の薬剤と粉体の形で配合する場合、実用面で支障とな
る品質のばらつきが生じ易い。したがって、保存時に吸
湿の少ない、安定な結晶質APSが望まれている。従
来、結晶質APS及びその製造方法についてはほとんど
知られておらず、わずかに特開平2−131494号公
報に、結晶質APSとその製造方法に関する記述がある
ぐらいである。2. Description of the Related Art L-ascorbic acid (vitamin C) has been known to have various physiological and pharmacological actions.
Above all, it has been used for whitening cosmetics because it has an effect of preventing melanin pigmentation. L-ascorbic acid is
It is a known fact that it is unstable to oxygen and heat, and it can be stabilized against oxygen and heat by phosphorylating the hydroxyl group at the 2-position of this unstable L-ascorbic acid. It is used as a water-soluble vitamin C derivative in the form of a salt of L-ascorbic acid-2-phosphate, especially a sodium salt, that is, APS. Since APS currently on the market is amorphous, it easily absorbs moisture during storage and easily forms powder nodules. A that absorbed moisture
PS causes caking or decreases fluidity,
When blended with other drugs in the form of a powder, variations in quality that hinder practical use are likely to occur. Therefore, a stable crystalline APS with little moisture absorption during storage is desired. Heretofore, crystalline APS and its production method have been scarcely known, and there is only a brief description of crystalline APS and its production method in JP-A-2-131494.
【0003】[0003]
【発明が解決しようとする課題】上記の特許の方法では
APSを含有する水溶液に、40〜80℃の温度で加熱
・還流しながら、メタノールを添加し、更に2〜10時
間加熱還流した後に、一晩かけて室温まで冷却して、結
晶質のAPSを析出させ取得している。この方法は有用
な結晶質APSの製造方法であるが、収率が71〜85
%と低い。また、APSを含有する水溶液を40〜80
℃という温度で長時間加熱するため、APSの分解がお
こり収率が低下する事や夾雑するL−アスコルビン酸が
分解して着色する欠点がある。更に、メタノールの添加
終了後2〜10時間加熱還流を継続する事や一晩かけて
室温まで冷却するなど生産性が低いという欠点がある。
このように従来の結晶質APSを製造する方法は、簡便
性、分解、収率、着色等の面で十分とは言い難い。本発
明はこのような欠点をなくし、分解や着色がないAPS
を収率よく、しかも容易に製造する方法を提供すること
を目的とする。In the method of the above-mentioned patent, methanol is added to an aqueous solution containing APS while heating and refluxing at a temperature of 40 to 80 ° C., and after further heating and refluxing for 2 to 10 hours, It is cooled to room temperature overnight to precipitate and obtain crystalline APS. This method is a useful method for producing crystalline APS, but yields 71-85.
% And low. In addition, the aqueous solution containing APS is 40-80.
Since heating is carried out at a temperature of ° C. for a long time, APS is decomposed to lower the yield, and contaminated L-ascorbic acid is decomposed and colored. Furthermore, there is a disadvantage that productivity is low such as continuing heating and refluxing for 2 to 10 hours after completion of addition of methanol and cooling to room temperature overnight.
As described above, the conventional method for producing crystalline APS is not sufficient in terms of simplicity, decomposition, yield, coloring, and the like. The present invention eliminates such disadvantages and eliminates APS without decomposition or coloring.
It is an object of the present invention to provide a method for easily producing a high yield.
【0004】[0004]
【課題を解決するための手段】本発明者らは、前記欠点
を改善するために鋭意検討した結果、驚くべき事に、有
機溶媒等の分散媒中で懸濁状態にある非晶質APSが加
熱により結晶質に変化すること、さらに、非晶質を含ま
ず高純度な結晶質APSも簡便且つ短時間に得られるこ
とを見出し、本発明に到達した。すなわち、本発明は、
分散媒中に非晶質APSを懸濁させ、加熱することを特
徴とする結晶質APSの製造方法である。Means for Solving the Problems The present inventors have conducted intensive studies in order to improve the above-mentioned disadvantages. As a result, surprisingly, the present inventors have found that amorphous APS suspended in a dispersion medium such as an organic solvent can be used. The present inventors have found that it changes to crystalline by heating, and that high-purity crystalline APS containing no amorphous material can be obtained easily and in a short time, and the present invention has been achieved. That is, the present invention
A method for producing a crystalline APS, comprising suspending an amorphous APS in a dispersion medium and heating.
【0005】[0005]
【発明の実施の形態】本発明の特徴は、非晶質APSを
分散媒中に懸濁させて加熱することであり、これに対し
分散媒を用いずに非晶質APSをそのまま加熱しても、
非晶質APSは結晶質APSに変化せず、黄色く着色
し、APSの分解が見られるだけである。例えば、窒素
雰囲気下、非晶質APSを60℃の温度に24時間曝
し、X線回折で結晶状態の変化を経時的に追った。24
時間経過してもAPSは非晶質を保っており、24時間
後の非晶質APSは、黄色く着色し、APS含量は初期
の97%にまで低下していた。また非晶質APSを水に
溶解して加熱し、水を蒸発乾固しても非晶質粉末となる
のみで結晶質APSにはならない。DESCRIPTION OF THE PREFERRED EMBODIMENTS A feature of the present invention is that amorphous APS is suspended in a dispersion medium and heated. On the other hand, amorphous APS is heated as it is without using a dispersion medium. Also,
Amorphous APS does not change to crystalline APS, is colored yellow, and only shows decomposition of APS. For example, the amorphous APS was exposed to a temperature of 60 ° C. for 24 hours in a nitrogen atmosphere, and the change in the crystalline state was followed over time by X-ray diffraction. 24
The APS remained amorphous even after a lapse of time, and after 24 hours, the amorphous APS was colored yellow, and the APS content had decreased to 97% of the initial value. Further, even if the amorphous APS is dissolved in water and heated, and the water is evaporated to dryness, only the amorphous powder is formed, but not the crystalline APS.
【0006】これに対し分散媒として有機溶媒を用い、
非晶質APSを有機溶媒に懸濁した状態で60℃の温度
で24時間曝しX線回折でAPSの結晶状態の変化を経
時的に追ったところ、30分で結晶質に変化した。24
時間後のAPS含量の減少はなく、着色も見られなかっ
た。このように、分散媒に懸濁することにより短時間に
効率よく、品質の良い結晶質APSを製造することがで
きる。On the other hand, an organic solvent is used as a dispersion medium,
When the amorphous APS was suspended in an organic solvent and exposed to a temperature of 60 ° C. for 24 hours, and the change in the crystal state of the APS was followed by X-ray diffraction, it changed to crystalline in 30 minutes. 24
There was no decrease in APS content after time and no coloration was seen. Thus, by suspending in a dispersion medium, a high-quality crystalline APS can be efficiently manufactured in a short time.
【0007】本発明の原料として用いられる非晶質(無
定形)APSは、例えば、アスコルビルPS[商品名、
昭和電工(株)製]として入手可能である。これら原料
の非晶質APSは、結晶質との混合物であっても良い。
上記した原料APSの粒子径は、1〜2000μmが好
ましい。粒子径が大きくなりすぎると加熱に要する時間
が長くなり、また細かすぎると取扱いにくい。したがっ
て、5〜500μmが特に好ましい。The amorphous (amorphous) APS used as the raw material of the present invention is, for example, Ascorbyl PS [trade name,
Manufactured by Showa Denko KK]. These raw materials of amorphous APS may be a mixture with crystalline materials.
The particle diameter of the above-mentioned raw material APS is preferably from 1 to 2000 μm. If the particle size is too large, the time required for heating becomes long, and if it is too small, it is difficult to handle. Therefore, 5 to 500 μm is particularly preferable.
【0008】本発明においては分散媒中にAPSを懸濁
させることが重要である。従ってAPSを溶解しない液
体であればよいが、これに適するものは主として有機溶
媒である。以下は有機溶媒を例にとり説明する。原料の
非晶質APSを下記に示すような有機溶媒に懸濁する。
この時の非晶質APSのスラリー濃度は0.1〜50%
(wt/V)である。スラリー濃度が高いと粘度が増加
し撹拌効率が悪くなり、スラリー濃度が低いと生産性が
悪くなる。したがって、5〜30%が特に好ましい。In the present invention, it is important to suspend APS in a dispersion medium. Therefore, any liquid that does not dissolve APS may be used, but suitable ones are mainly organic solvents. The following description is made using an organic solvent as an example. The raw material amorphous APS is suspended in an organic solvent as shown below.
At this time, the slurry concentration of the amorphous APS is 0.1 to 50%.
(Wt / V). If the slurry concentration is high, the viscosity increases and the stirring efficiency becomes poor, and if the slurry concentration is low, the productivity becomes poor. Therefore, 5 to 30% is particularly preferable.
【0009】本発明で用いられる有機溶媒は、トルエ
ン、キシレン等の芳香族炭化水素、脂肪族アルコール、
例えばメタノール、エタノール、イソプロピルアルコー
ル等の炭素数4以下の低級脂肪族アルコール類、脂肪族
ケトン、例えばシクロヘキサノン、アセトン等の炭素数
6以下の脂肪族ケトン類、および脂肪族エーテル、例え
ばテトラヒドロフラン、1,4−ジオキサン等の環状エ
ーテル類が例示される。これらの溶媒は単独でも、混合
しても用いることができる。その他、脂肪族炭化水素や
ハロゲン化炭化水素を用いても、非晶質APSから結晶
質APSへの変換に対する本質的な問題はないが、有機
溶媒の引火性や毒性の観点から前記のものが好ましい。
有機溶媒は、結晶質APSを単離した後、蒸留等の操作
によって回収されるため、低沸点で安価な溶媒が好まし
い。したがって、メタノール、アセトンが特に好まし
い。また、本発明に用いられる有機溶媒中にAPSを溶
解しない範囲で水分が夾雑していてもかまわない。非晶
質APSは有機溶媒には不溶であるが、水には極めて良
く溶解するため、有機溶媒の種類によっても異なるが、
有機溶媒中に夾雑する水分の量は、40%(wt/V)
以下が好ましい。The organic solvent used in the present invention includes aromatic hydrocarbons such as toluene and xylene, aliphatic alcohols,
For example, lower aliphatic alcohols having 4 or less carbon atoms such as methanol, ethanol and isopropyl alcohol, aliphatic ketones such as cyclohexanone and aliphatic ketones having 6 or less carbon atoms such as acetone, and aliphatic ethers such as tetrahydrofuran and 1,1 Examples include cyclic ethers such as 4-dioxane. These solvents can be used alone or in combination. In addition, even if an aliphatic hydrocarbon or a halogenated hydrocarbon is used, there is no essential problem with respect to the conversion of the amorphous APS to the crystalline APS. preferable.
Since the organic solvent is recovered by an operation such as distillation after isolating the crystalline APS, an inexpensive solvent having a low boiling point is preferable. Therefore, methanol and acetone are particularly preferred. Further, water may be contaminated within a range that does not dissolve APS in the organic solvent used in the present invention. Amorphous APS is insoluble in organic solvents, but is very well soluble in water.
The amount of water contaminating in the organic solvent is 40% (wt / V)
The following is preferred.
【0010】非晶質APSを有機溶媒に添加し、撹拌し
て懸濁させ、加熱する。加熱する温度は40〜120℃
が好ましい。温度が低いと加熱に要する時間が長くな
り、温度が高いとAPSの分解が促進されるため、50
〜100℃が特に好ましい。通常、加熱に要する時間は
0.3〜12時間である。時間が短すぎると非晶質から
結晶質への変換が完結せず、時間が長すぎると非晶質か
ら結晶質への変換にはなんら支障はないが、無意味にプ
ラントを占有するため経済的に不利である。したがっ
て、0.5〜7時間が特に好ましい。[0010] The amorphous APS is added to the organic solvent, suspended by stirring and heated. Heating temperature is 40-120 ° C
Is preferred. When the temperature is low, the time required for heating becomes long, and when the temperature is high, the decomposition of APS is promoted.
-100 ° C is particularly preferred. Usually, the time required for heating is 0.3 to 12 hours. If the time is too short, the conversion from amorphous to crystalline is not completed, and if the time is too long, there is no hindrance to the conversion from amorphous to crystalline, but economically because the plant is meaninglessly occupied. Disadvantageous. Therefore, 0.5 to 7 hours is particularly preferable.
【0011】加熱終了後、室温まで冷却する。冷却後、
熟成を行う必要は特にない。これら結晶質APSを含有
するスラリーは遠心分離機等の装置を用いて単離され、
前記有機溶媒で充分洗浄した後、真空乾燥等の処理によ
って、白色の結晶質APSが高純度かつ高収率に得られ
る。After the completion of the heating, the system is cooled to room temperature. After cooling,
There is no particular need for aging. The slurry containing the crystalline APS is isolated using a device such as a centrifuge,
After sufficiently washing with the organic solvent, white crystalline APS can be obtained with high purity and high yield by treatment such as vacuum drying.
【0012】本発明の方法によって何故非晶質APSが
結晶質に変わるか、その作用機構は定かでないが、加熱
中にAPS中の水和水が減少することから、有機溶媒中
におけるこの水和水の減少が結晶化に何らかの形で関与
していることが考えられる。It is not clear why the amorphous APS is changed to crystalline by the method of the present invention, but the hydration water in the APS decreases during heating. It is conceivable that the water loss is involved in the crystallization in some way.
【0013】本発明で得られる結晶質APSは以下の物
理化学的性質を示す。 (1)X線回折スペクトル;CuKα線、40kV、4
0mAの条件で測定して得られたX線回折スペクトルを
図1に示す。その面間隔d(Å)と比較強度を表1に示
す。尚、参考までに比較として非晶質APSのX線回折
スペクトルを図2に示す。 (2)赤外吸収スペクトル;KBr法により測定した結果を図3に示す。その特 徴的な吸収(波数)は以下の通りである。 3400cm-1 :O−H吸収帯 1600cm-1 :C=O伸縮振動の吸収帯 1000〜1200cm-1 :P−Oの吸収帯 (3)溶解性:水に可溶(25℃における溶解度は38%(wt/V) 有機溶媒に不溶(アルコール類、クロロホルム) (4)結晶形:10〜500μmの微細結晶集合体(顕
微鏡観察)The crystalline APS obtained by the present invention has the following physicochemical properties. (1) X-ray diffraction spectrum; CuKα ray, 40 kV, 4
FIG. 1 shows an X-ray diffraction spectrum obtained under the condition of 0 mA. Table 1 shows the surface spacing d (Å) and the comparative strength. For reference, an X-ray diffraction spectrum of amorphous APS is shown in FIG. 2 for comparison. (2) Infrared absorption spectrum; FIG. 3 shows the result measured by the KBr method. The characteristic absorption (wave number) is as follows. 3400 cm -1: O-H absorption band 1600 cm -1: C = absorption band of O stretching vibration 1000 to 1200 -1: absorption band of P-O (3) Solubility: Solubility in soluble (25 ° C. in water 38 % (Wt / V) Insoluble in organic solvent (alcohols, chloroform) (4) Crystal form: fine crystal aggregate of 10 to 500 μm (microscopic observation)
【0014】本発明の製造方法によって得られる結晶質
APSは、吸湿性が少なく、安定性に優れており、例え
ば医薬品(例、口腔用薬剤、点眼剤、浴用剤等)、化粧
品(例、化粧水、乳液、クリーム、パック等)、食品
(例、パン等)および動物用飼料(例、海老、鮭、ハマ
チ、鰻、鯉等の養殖用飼料)などとして用いられる。The crystalline APS obtained by the production method of the present invention has low hygroscopicity and excellent stability. For example, it can be used for pharmaceuticals (eg, oral medicines, eye drops, bath agents, etc.), cosmetics (eg, cosmetics) It is used as water, emulsion, cream, pack, etc., food (eg, bread, etc.) and animal feed (eg, shrimp, salmon, hamachi, eel, carp, etc. feed for aquaculture).
【0015】[0015]
【実施例】次に、実施例によって、本発明を更に詳しく
説明するが、本発明はこれら実施例に限定されるもので
はない。また、以下、実施例1〜7で得られたAPS
は、上述の結晶性APSと同等の物理化学的性質を示し
た。なお、各実施例、比較例に用いた非晶質APSは昭
和電工(株)製、商品名アスコルビルPS、粒度1〜5
0μmである。Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples. Also, hereinafter, the APS obtained in Examples 1 to 7
Showed the same physicochemical properties as the crystalline APS described above. The amorphous APS used in each of Examples and Comparative Examples was manufactured by Showa Denko KK, trade name: Ascorbyl PS, particle size: 1 to 5
0 μm.
【0016】実施例1 撹拌下、99%メタノール1000mlに非晶質APS
200gを加え懸濁液を調整し、60℃に加温した。こ
の温度で2時間加熱を継続し、室温まで冷却した。遠心
分離機を用いてAPSを濾取し、得られた湿体を99%
メタノールで充分洗浄した。真空下、40℃で乾燥し、
純度100%のAPSを198g(収率99%)得た。
X線回折により、得られたAPSは結晶質であることを
確認した。Example 1 Amorphous APS was added to 1000 ml of 99% methanol under stirring.
The suspension was adjusted by adding 200 g and heated to 60 ° C. Heating was continued at this temperature for 2 hours and cooled to room temperature. APS was collected by filtration using a centrifugal separator, and the obtained wet body was 99%
Washed thoroughly with methanol. Dried at 40 ° C. under vacuum,
198 g (99% yield) of 100% pure APS was obtained.
X-ray diffraction confirmed that the obtained APS was crystalline.
【0017】実施例2 撹拌下、99%メタノール1000mlに非晶質APS
400gを加え懸濁液を調整し、60℃に加温した。こ
の温度で4時間加熱を継続し、室温まで冷却した。遠心
分離機を用いてAPSを濾取し、得られた湿体を99%
メタノールで充分洗浄した。真空下、40℃で乾燥し、
純度100%のAPSを396g(収率99%)得た。
X線回折により、得られたAPSは結晶質であることを
確認した。Example 2 Under stirring, amorphous APS was added to 1000 ml of 99% methanol.
The suspension was adjusted by adding 400 g and heated to 60 ° C. Heating was continued at this temperature for 4 hours and cooled to room temperature. APS was collected by filtration using a centrifugal separator, and the obtained wet body was 99%
Washed thoroughly with methanol. Dried at 40 ° C. under vacuum,
396 g (99% yield) of 100% pure APS was obtained.
X-ray diffraction confirmed that the obtained APS was crystalline.
【0018】実施例3 撹拌下、70%(wt/V)メタノールの水−メタノー
ル溶液1000mlに非晶質APS200gを加え懸濁
液を調整し、70℃に加温した。この温度で4時間加熱
を継続し、室温まで冷却した。遠心分離機を用いてAP
Sを濾取し、得られた湿体を上記と同じ水−メタノール
溶液で充分洗浄した。真空下、40℃で乾燥し、純度1
00%のAPSを192g(収率96%)得た。X線回
折により、得られたAPSは結晶質であることを確認し
た。Example 3 200 g of amorphous APS was added to 1000 ml of a 70% (wt / V) methanol-water / methanol solution with stirring to prepare a suspension, which was heated to 70 ° C. Heating was continued at this temperature for 4 hours and cooled to room temperature. AP using centrifuge
S was collected by filtration, and the obtained wet body was sufficiently washed with the same water-methanol solution as described above. Dry at 40 ° C under vacuum, purity 1
192 g (96% yield) of 00% APS was obtained. X-ray diffraction confirmed that the obtained APS was crystalline.
【0019】実施例4 撹拌下、実施例3と同じ水−メタノール溶液1000m
lに非晶質APS50gを加え懸濁液を調整し、70℃
に加温した。この温度で2時間加熱を継続し、室温まで
冷却した。遠心分離機を用いてAPSを濾取し、得られ
た湿体を上記と同じ水−メタノール溶液で充分洗浄し
た。真空下、40℃で乾燥し、純度100%のAPSを
43g(収率86%)得た。X線回折により、得られた
APSは結晶質であることを確認した。Example 4 The same water-methanol solution as in Example 3 (1000 m) was stirred.
The suspension was adjusted by adding 50 g of amorphous APS to
Was heated. Heating was continued at this temperature for 2 hours and cooled to room temperature. The APS was collected by filtration using a centrifuge, and the obtained wet body was sufficiently washed with the same water-methanol solution as described above. Drying at 40 ° C. under vacuum yielded 43 g (86% yield) of 100% pure APS. X-ray diffraction confirmed that the obtained APS was crystalline.
【0020】実施例5 撹拌下、99%アセトン1000mlに非晶質APS5
0gを加え懸濁液を調整し、50℃に加温した。この温
度で7時間加熱を継続し、室温まで冷却した。遠心分離
機を用いてAPSを濾取し、得られた湿体を99%アセ
トンで充分洗浄した。真空下、40℃で乾燥し、純度1
00%のAPSを49g(収率98%)得た。X線回折
により、得られたAPSは結晶質であることを確認し
た。Example 5 Under stirring, amorphous APS5 was added to 1000 ml of 99% acetone.
The suspension was adjusted by adding 0 g and heated to 50 ° C. Heating was continued at this temperature for 7 hours and cooled to room temperature. APS was collected by filtration using a centrifugal separator, and the obtained wet body was sufficiently washed with 99% acetone. Dry at 40 ° C under vacuum, purity 1
49 g (98% yield) of 00% APS was obtained. X-ray diffraction confirmed that the obtained APS was crystalline.
【0021】実施例6 撹拌下、99%トルエン1000mlに非晶質APS2
00gを加え懸濁液を調整し、100℃に加温した。こ
の温度で1時間加熱を継続し、室温まで冷却した。遠心
分離機を用いてAPSを濾取し、得られた湿体を99%
アセトンで充分洗浄した。真空下、55℃で乾燥し、純
度100%のAPSを195g(収率98%)得た。X
線回折により、得られたAPSは結晶質であることを確
認した。Example 6 Amorphous APS2 was added to 1000 ml of 99% toluene under stirring.
The suspension was adjusted by adding 00 g and heated to 100 ° C. Heating was continued at this temperature for 1 hour and cooled to room temperature. APS was collected by filtration using a centrifugal separator, and the obtained wet body was 99%
It was thoroughly washed with acetone. It was dried at 55 ° C. under vacuum to obtain 195 g (yield 98%) of 100% pure APS. X
The obtained APS was confirmed to be crystalline by line diffraction.
【0022】実施例7 撹拌下、99%1,4−ジオキサン1000mlに非晶
質APS200gを加え懸濁液を調整し、90℃に加温
した。この温度で1時間加熱を継続し、室温まで冷却し
た。遠心分離機を用いてAPSを濾取し、得られた湿体
を99%アセトンで充分洗浄した。真空下、50℃で乾
燥し、純度100%のAPSを195g(収率98%)
得た。X線回折により、得られたAPSは結晶質である
ことを確認した。Example 7 Under stirring, 200 g of amorphous APS was added to 1000 ml of 99% 1,4-dioxane to prepare a suspension, which was heated to 90 ° C. Heating was continued at this temperature for 1 hour and cooled to room temperature. APS was collected by filtration using a centrifugal separator, and the obtained wet body was sufficiently washed with 99% acetone. After drying at 50 ° C. under vacuum, 195 g of 100% pure APS (98% yield)
Obtained. X-ray diffraction confirmed that the obtained APS was crystalline.
【0023】比較例1 撹拌下、実施例3と同じ水−メタノール溶液1000m
lに非晶質APS200gを加え懸濁液を調整し、室温
(20℃)のまま24時間撹拌を継続した。遠心分離機
を用いてAPSを濾取し、得られた湿体を上記と同じ水
−メタノール溶液で充分洗浄した。真空下、40℃で乾
燥し、純度100%のAPSを192g(収率96%)
得た。X線回折により、得られたAPSは非晶質のまま
であることを確認した。Comparative Example 1 The same water-methanol solution of 1000 m as in Example 3 was stirred under stirring.
200 g of amorphous APS was added to 1 to prepare a suspension, and stirring was continued for 24 hours at room temperature (20 ° C.). The APS was collected by filtration using a centrifuge, and the obtained wet body was sufficiently washed with the same water-methanol solution as described above. It is dried at 40 ° C. under vacuum, and 192 g of APS having a purity of 100% (96% yield).
Obtained. X-ray diffraction confirmed that the obtained APS remained amorphous.
【0024】比較例2 撹拌下、99%トルエン1000mlに非晶質APS2
00gを加え懸濁液を調整し、室温のまま24時間撹拌
を継続した。遠心分離機を用いてAPSを濾取し、得ら
れた湿体を99%トルエンで充分洗浄した。真空下、5
5℃で乾燥し、純度100%のAPSを196g(収率
98%)得た。X線回折により、得られたAPSは非晶
質であることを確認した。Comparative Example 2 Amorphous APS2 was added to 1000 ml of 99% toluene under stirring.
The suspension was adjusted by adding 00 g, and stirring was continued for 24 hours at room temperature. APS was collected by filtration using a centrifugal separator, and the obtained wet body was sufficiently washed with 99% toluene. Under vacuum, 5
After drying at 5 ° C., 196 g (yield 98%) of 100% pure APS was obtained. X-ray diffraction confirmed that the obtained APS was amorphous.
【0025】[0025]
【表1】 [Table 1]
【0026】[0026]
【発明の効果】本発明の製造方法により、簡便且つ高収
率に結晶質L−アスコルビン酸−2−リン酸エステルナ
トリウム塩を製造することができる。本発明の製造方法
により得られる結晶質L−アスコルビン酸−2−リン酸
エステルナトリウム塩は化粧料、飼料、医薬、食品添加
物等に用いられる。According to the production method of the present invention, crystalline L-ascorbic acid-2-phosphate sodium salt can be produced simply and in high yield. The crystalline L-ascorbic acid-2-phosphate sodium salt obtained by the production method of the present invention is used for cosmetics, feed, medicine, food additives and the like.
【図1】本発明で得られる結晶質L−アスコルビン酸−
2−リン酸エステルナトリウム塩のX線回折スペクトル
(CuKα線、40kV、40mA)である。図中、縦
軸は回折強度(単位:カウント/秒)を、横軸は回折角
(単位:2θ(°))を表す。FIG. 1 shows crystalline L-ascorbic acid obtained by the present invention.
2 is an X-ray diffraction spectrum (CuKα ray, 40 kV, 40 mA) of 2-phosphate sodium salt. In the figure, the vertical axis represents the diffraction intensity (unit: count / second), and the horizontal axis represents the diffraction angle (unit: 2θ (°)).
【図2】非晶質L−アスコルビン酸−2−リン酸エステ
ルナトリウム塩のX線回折スペクトル(CuKα線、4
0kV、40mA)である。図中、縦軸は回折強度(単
位:カウント/秒)を、横軸は回折角(単位:2θ
(°))を表す。FIG. 2 shows an X-ray diffraction spectrum of an amorphous sodium salt of L-ascorbic acid-2-phosphate (CuKα ray,
0 kV, 40 mA). In the figure, the vertical axis represents the diffraction intensity (unit: count / second), and the horizontal axis represents the diffraction angle (unit: 2θ).
(°)).
【図3】本発明で得られた結晶質L−アスコルビン酸−
2−リン酸エステルナトリウム塩の赤外線吸収スペクト
ルである。FIG. 3 shows crystalline L-ascorbic acid obtained in the present invention.
It is an infrared absorption spectrum of 2-phosphate sodium salt.
Claims (5)
2−リン酸エステルナトリウム塩を懸濁させ、加熱する
ことを特徴とする結晶質L−アスコルビン酸−2−リン
酸エステルナトリウム塩の製造方法。An amorphous L-ascorbic acid in a dispersion medium.
A method for producing crystalline sodium salt of L-ascorbic acid-2-phosphate, comprising suspending 2-phosphate sodium salt and heating.
製造方法。2. The method according to claim 1, wherein the dispersion medium is an organic solvent.
コール、脂肪族ケトンおよび脂肪族エーテルから選ばれ
る少なくとも1種である請求項2記載の製造方法。3. The method according to claim 2, wherein the organic solvent is at least one selected from aromatic hydrocarbons, aliphatic alcohols, aliphatic ketones and aliphatic ethers.
ケトンがアセトンである請求項3記載の製造方法。4. The method according to claim 3, wherein the aliphatic alcohol is methanol and the aliphatic ketone is acetone.
求項1〜4のいずれかに記載の製造方法。5. The method according to claim 1, wherein the heating temperature is 40 to 120 ° C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16996296A JP3843490B2 (en) | 1996-06-28 | 1996-06-28 | Method for producing crystalline L-ascorbic acid-2-phosphate sodium salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16996296A JP3843490B2 (en) | 1996-06-28 | 1996-06-28 | Method for producing crystalline L-ascorbic acid-2-phosphate sodium salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH1017580A true JPH1017580A (en) | 1998-01-20 |
| JP3843490B2 JP3843490B2 (en) | 2006-11-08 |
Family
ID=15896062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16996296A Expired - Fee Related JP3843490B2 (en) | 1996-06-28 | 1996-06-28 | Method for producing crystalline L-ascorbic acid-2-phosphate sodium salt |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3843490B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6299912B1 (en) | 1999-04-23 | 2001-10-09 | Showa Denko Kabushiki Kaisha | Preparation for administration to animals and feeding method thereof |
| JPWO2005073239A1 (en) * | 2004-01-30 | 2008-01-10 | 日本新薬株式会社 | Method for purifying quinolinecarboxylic acid derivatives |
-
1996
- 1996-06-28 JP JP16996296A patent/JP3843490B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6299912B1 (en) | 1999-04-23 | 2001-10-09 | Showa Denko Kabushiki Kaisha | Preparation for administration to animals and feeding method thereof |
| JPWO2005073239A1 (en) * | 2004-01-30 | 2008-01-10 | 日本新薬株式会社 | Method for purifying quinolinecarboxylic acid derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3843490B2 (en) | 2006-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960013445B1 (en) | Mometasone furoate monohydrate, process for making the same | |
| US5463116A (en) | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them | |
| JP2001508077A (en) | Novel modification of 2-amino-4- (4-fluorobenzylamino) -1-ethoxycarbonyl-aminobenzene and process for producing the same | |
| CN102448963A (en) | Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one | |
| JP2003522175A (en) | Linezolid crystal form II | |
| KR101929960B1 (en) | Crystalline form of ertapenem sodium and preparation method therefor | |
| KR100403256B1 (en) | Crystalline N-Acetyl Neuraminic Acid Derivatives and Processes for Their Preparation | |
| CN111868054B (en) | Co-crystals of fruquintinib, preparation methods, compositions and uses thereof | |
| US20050020675A1 (en) | Bicalutamide polymorphs | |
| CN103755723B (en) | A kind of preparation method of rifampicin I crystal form | |
| CN103554203A (en) | Amorphous crystal of tylonolide, and preparation method thereof | |
| JP3135672B2 (en) | Crystals and solvates of macrolide antibiotics | |
| JPH1017580A (en) | Production of crystalline l-ascorbic 2-phosphorate sodium salt | |
| RU2228931C2 (en) | Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n- (pentylsulfonyl)-3h-benzimidazole-5-carboxamide | |
| CN105315266B (en) | The crystal form of 1- { the fluoro- 4- of 2- [5- (4- isobutyl phenenyl) -1,2,4- oxadiazoles -3- base]-benzyl } -3- azetidinecarboxylic acid | |
| KR20050033525A (en) | New anhydrous crystalline forms of gabapentin | |
| CS195746B2 (en) | Process for preparing crystalline methanolate of natrium salt of cephamandole | |
| CN105646521B (en) | A kind of method for crystallising of moxidectin | |
| CN109400539A (en) | A kind of methylpyrazine derivative semihydrate | |
| HU176213B (en) | Process for preparing a new crystallic modification of the sodium salt of 7beta-cyanacetylamino-3-acetoxymethyl-cef-3-em-4-carboxylic acid | |
| CN106928228A (en) | Ao Gelieting salt and its crystal formation, their preparation method and pharmaceutical composition | |
| JPS6225668B2 (en) | ||
| CN107698563B (en) | Method for preparing neratinib maleate crystal form | |
| JP3105572B2 (en) | Selective production of hydrate | |
| CN105636964B (en) | I-type crystal of l-alanine-(14-oridonin) ester trifluoroacetate and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050510 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050531 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060725 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060807 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090825 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120825 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120825 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150825 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |